

Cortellis Explained: A Guide to the Life Sciences Platform

11/28/2025 • 30 min read

[cortellis](#) [clarivate](#) [life sciences intelligence](#) [drug development](#) [r&d intelligence](#) [clinical trials intelligence](#)
[regulatory intelligence](#) [pharmaceutical data](#)



[Revised April 12, 2026]

Executive Summary

Clarivate's **Cortellis** is a comprehensive life sciences intelligence platform encompassing [drug discovery, development](#), regulatory, and commercial information. Launched originally by Thomson Reuters in 2012 and expanded under Clarivate (spun off in 2016), Cortellis integrates billions of curated data points (patents, trials, targets, safety reports, etc.) into a unified system to accelerate R&D decision-making (^[1] www.fiercebitech.com) (^[2] clarivate.com). Its modular suite—**Competitive Intelligence, Deals Intelligence, Clinical Trials Intelligence, Regulatory Intelligence, CMC Intelligence, Generics Intelligence, Drug Discovery Intelligence** (including the Integrity and MetaCore databases), **Digital Health Intelligence**, and **Safety/Off-X Intelligence**—provides end-to-end coverage from target identification through market launch (^[3] clarivate.com) (^[4] ir.clarivate.com). For example, as of 2019 Clarivate reported Cortellis covers over 70,000 pipeline targets, 90,000 deals and 325,000 clinical trials (^[5] clarivate.com), spans 80+ regulatory jurisdictions (^[6] clarivate.com) and includes databases of 1.2 million patents (Newport generics) (^[7] clarivate.com), 540,000 bioactive compounds (Integrity) (^[8] clarivate.com), and 1.7 million molecular interactions (MetaCore) (^[9] clarivate.com). Cortellis also continuously evolves its technology – for example, launching an AI-driven “Enhanced Search” in 2023 to allow natural-language queries across the platform (^[10] clarivate.com) (^[11] clarivate.com) a beta **AI-powered Regulatory Assistant** in August 2025 (fully launched to all customers in December 2025) to answer regulatory queries with context and references (^[12] clarivate.com) (^[13] clarivate.com), and in March 2026 integrating Cortellis Regulatory Intelligence with Anthropic's Claude AI via the open Model Context Protocol (MCP) to embed authoritative regulatory content into AI workflows (^[13] clarivate.com). These capabilities are already being adopted by leading firms: Biogen, for instance, praised Cortellis's APIs as “exceed [ing] expectations” for delivering real-time R&D content into their systems (^[14] www.fiercebitech.com), and Moderna has reported that Cortellis's AI assistant will “save significant time and resources” versus manual searching (^[15] clarivate.com).

Despite its power, Cortellis faces competition and uncertainty. Competitors like Evaluate, IQVIA, and Norstell's Citeline offer overlapping services (market forecasts, real-world data, clinical trial databases), requiring users to choose tools carefully (^[16] intuitionlabs.ai) (^[17] intuitionlabs.ai). Experts note that Cortellis's depth and breadth can be complex and costly for some users (^[18] intuitionlabs.ai). Notably, in February 2026, Clarivate announced it is exploring a sale of its entire Life Sciences & Healthcare segment — which includes Cortellis, DRG Fusion, BioWorld, and the consulting team — to focus on its Academia & Government and Intellectual Property businesses (^[19] clarivate.com). The LS&H segment generated \$389.8 million in revenue in 2025 (down 6.9% year-over-year), and Morgan Stanley has been appointed as financial advisor. Despite this strategic shift, Cortellis remains a cornerstone of modern drug intelligence: it accelerates innovation by breaking information silos and applying advanced analytics, while its ongoing AI and data-expansion initiatives continue to transform how R&D, regulatory and commercial teams access insights.

Introduction and Background

Drug development and healthcare innovation have become increasingly data-intensive. Pharmaceutical and biotech R&D teams must navigate fragmented information sources – including patents, [preclinical studies](#), clinical trials, regulatory filings, deals and market data – across multiple global jurisdictions. Integrating and analyzing this complexity is crucial but challenging. **Cortellis** is Clarivate's response: a unified intelligence platform that curates and connects vast life sciences datasets into actionable knowledge. By consolidating disparate data (often previously siloed or manually curated) into one “single point of access,” Cortellis helps organizations make faster, evidence-based decisions from discovery through commercialization (^[2] clarivate.com) (^[10] clarivate.com).

Clarivate, the parent company, was formed in 2016 when private equity investors acquired Thomson Reuters' Intellectual Property & Science division (^[20] pharmaceuticalintelligence.com). The roots of Cortellis trace back to Thomson Reuters'

pioneering scientific intelligence products (formerly part of Thomson Scientific). Under Thomson Reuters, Cortellis was introduced as a next-generation life sciences platform: for example, in 2012 Thomson Reuters launched “**Cortellis for Informatics**”, leveraging web services and APIs to deliver real-time R&D data on pipelines, drug targets, patents, and more to customers’ internal systems (^[21] www.fiercebitech.com) (^[14] www.fiercebitech.com). Hence Cortellis was conceived as an integrated R&D dashboard, surpassing legacy portals by enabling data feeds into company databases and applications (^[22] www.fiercebitech.com) (^[23] www.fiercebitech.com).

When Clarivate became independent, it continued and expanded this vision. Today Cortellis is part of Clarivate’s Life Sciences intelligence portfolio, alongside Web of Science and analytics tools. Clarivate has aggressively grown this business through acquisitions: notably, it acquired Decision Resources Group (DRG) in 2020, doubling the Life Sciences segment and aiming to offer an “end-to-end” data platform covering discovery through commercialization (^[24] clarivate.com) (^[25] clarivate.com). Other purchases – such as SequenceBase (patents), bioinformatics/data analysis companies, and in March 2024, **MotionHall**, a Silicon Valley AI start-up whose IP is being used to enhance Cortellis search capabilities and power a new Business Development & Licensing Enterprise Workbench (^[26] clarivate.com) – further enriched Cortellis’s datasets. Clarivate reports that in 2019 *Science & Life Sciences* products (including Cortellis) accounted for a majority of its revenues (^[27] clarivate.com), underscoring the strategic importance of Cortellis to the company’s growth.

As of early 2026, Cortellis stands as a broad ecosystem of modules. Its intuitive cloud platform (called **Cortellis Cloud**, launched 2019) harmonizes content from thousands of sources into one scalable, on-demand architecture (^[2] clarivate.com). On top of this, Clarivate offers specialized intelligence products and APIs: *Product Intelligence* (global drug pipelines), *Clinical Trials Intelligence* (enhanced trial registries), *Regulatory Intelligence* (global approvals and requirements), *Deals Intelligence* (licensing and M&A terms), *Competitive Intelligence* dashboards, *CMC Intelligence* (chemistry/manufacturing controls), *Generics Intelligence* (supply chain and API data), *Drug Discovery Intelligence* (chemistry/biologics targets), *Digital Health Intelligence* (apps/wearables ecosystems), *Safety Intelligence* (pharmacovigilance), and more (^[28] intuitionlabs.ai) (^[4] ir.clarivate.com). Cortellis also intersects with Clarivate’s other offerings (e.g. **MetaCore** for systems biology, **Integrity** for preclinical R&D, **Off-X** for safety) to cover specialty needs. Throughout this report, we analyze these components, their data coverage, case examples of use, and how Cortellis’s continuous integration of AI and data innovations positions it for future impact.

History and Evolution of Cortellis

Origins (2012–2015): The Cortellis brand emerged in early 2012. As reported by *Fierce Biotech*, Thomson Reuters announced “**Cortellis for Informatics**” on February 28, 2012, describing it as an innovative API-driven platform to “speed access to critical life sciences R&D information” (^[21] www.fiercebitech.com). Cortellis for Informatics provided web services for drug, target, patents, trials and analytic data, combining Thomson Reuters’ own curated sources with public data. Notably, early adopters like Biogen Idec praised it: Biogen’s Dr. William Hayes confirmed the APIs “exceed [ed] expectations” by integrating Thomson Reuters content into the systems driving their drug research (^[14] www.fiercebitech.com). By offering rich pipeline and competitive intelligence via programmable interfaces, Cortellis moved beyond static databases and enabled researchers to embed Zimmermann’s intelligence directly into their workflows (^[1] www.fiercebitech.com) (^[23] www.fiercebitech.com).

Clarivate spinoff and integration (2016–2019): In 2016 Clarivate (formerly CPA Global; spun off from Thomson Reuters) took ownership of Cortellis. Under Clarivate’s stewardship, Cortellis became the backbone of a unified Life Sciences intelligence division. In early 2019, Clarivate launched **Cortellis Cloud** (^[29] clarivate.com), an AWS-based unified platform designed to integrate all Cortellis solutions under one infrastructure. The Cortellis Cloud “harmonizes datapoints from thousands of sources within a single unified platform,” according to Clarivate (^[2] clarivate.com). This made Cortellis the industry’s “richest resource” for life science analytics, delivering real-time insights and scalable machine-learning capabilities across R&D (^[2] clarivate.com). With Cloud, Clarivate enabled direct data feeds and API integration for

partners, ensuring that new content and features could be deployed instantly and shared via dashboards or intranets (^[30] clarivate.com) (^[2] clarivate.com).

At the same time Cortellis was modularized and expanded. Clarivate segmented Cortellis into discrete intelligence products. For example, in July 2020 Clarivate introduced **Cortellis Generics Intelligence** (built on the legacy Newport platform), explicitly aimed at generics drug manufacturers and API suppliers (^[31] ir.clarivate.com). This module aggregates generics-specific data – including market sales, patent challenge status (e.g. Paragraph IV listings), and API manufacturer information – to support supply-chain and market-entry decisions (^[32] ir.clarivate.com) (^[33] ir.clarivate.com). Similarly, in August 2019 Clarivate launched **Cortellis Digital Health Intelligence**, the “first-of-its-kind” solution covering the emerging digital health [apps and devices] ecosystem (^[34] ir.clarivate.com). This new Cortex data stream curates news, health app reviews, tech deals and trial designs related to digital therapeutics and monitoring; at launch it included ~6,000 press releases, 4,000+ app reviews and 3,000+ digital-health deals (^[4] ir.clarivate.com). These moves signaled Clarivate’s strategy: extending Cortellis beyond legacy pharmaceutical data into adjacent domains (generics supply and digital care) while leveraging the common Cortellis Cloud infrastructure (^[35] ir.clarivate.com) (^[36] ir.clarivate.com).

Recent Innovations (2020s): Clarivate’s acquisitions and AI investments have further transformed Cortellis. Acquiring DRG in 2020 added deep commercialization expertise to the Cortellis portfolio (combining pipeline focus with patient-centric market data (^[37] clarivate.com)). SequenceBase broadened patent chemistry data. In 2023 Clarivate infused generative AI: its **Enhanced Search** platform allows natural-language querying across Cortellis data assets (^[10] clarivate.com). According to Clarivate, this GenAI-powered search ingests *billions* of proprietary data points and over a century of expertise to answer complex drug-development questions quickly (^[10] clarivate.com) (^[11] clarivate.com). Drugs/Trials/Deals databases are integrated in this search interface, which yields “precise, concise and immediate answers” with transparent references – for example, it highlights key facts and avoids the hallucinations common in generic AI chatbots (^[38] clarivate.com) (^[11] clarivate.com). In August 2025 Clarivate debuted an **AI-powered Regulatory Assistant** within Cortellis Regulatory Intelligence in beta, and by December 2025 it was fully launched to all Cortellis Regulatory Intelligence customers (^[12] clarivate.com) (^[13] clarivate.com). Powered by agentic AI, this chat-based tool answers compliance questions conversationally, citing relevant regulations and guidance. Key features include quick document summarization, the ability to compare draft and final guidance in seconds, and multilingual support — allowing users to query “in preferred languages” and retrieve personalized, context-aware guidance instantly (^[12] clarivate.com). In a further expansion, Clarivate announced in March 2026 that Cortellis Regulatory Intelligence data would be integrated into Anthropic’s **Claude AI** via the open **Model Context Protocol (MCP)**, embedding authoritative regulatory content directly into AI workflows used by biopharma and medtech organizations (^[39] stocktitan.net). Such innovations indicate Cortellis’s evolution from a static data portal into an interactive, AI-native system, continuously updated with new content and integrated into modern AI infrastructure.

Cortellis Products and Modules

Cortellis comprises a family of specialized intelligence solutions. In practice, clients often subscribe to one or more Cortellis modules based on their needs (R&D, regulatory, commercial, etc.), while leveraging the unified Cortellis Cloud for integration. Below is a high-level overview of key Cortellis components by activity area:

- **Cortellis Competitive Intelligence (CI) & Pipeline Analytics.** Aggregates detailed pipeline data and competitor profiles. Users can monitor 70,000+ drug targets and molecules in development, including clinical status, indications, mechanism-of-action, and company strategy (^[5] clarivate.com). CI integrates data from Cortellis Product Intelligence (global pipeline database) and Deal Intelligence, enabling users to track licensing/M&A events. For example, its “business development” analytics cover **90,000+ deals** between companies worldwide (^[5] clarivate.com). Clarivate claims that decisions on 70% of top industry licensing deals are informed by its Cortellis intelligence (^[27] clarivate.com).
- **Cortellis Clinical Trials Intelligence.** Enhanced clinical trial registry data (including proprietary additions). Users can search and filter global trial records (~325,000+ trials) by therapy area, sponsor, phase, locations, and outcomes

^[5] clarivate.com). The system provides analytics for site selection, patient population, enrollment forecasts, and competitive trial benchmarking. Integration with CI and CI's analytics means that clinical programs can be evaluated in the context of pipeline competitors and regulatory plans.

- Cortellis Regulatory Intelligence.** Comprehensive global regulatory database. It tracks drug and biologic marketing applications, approvals, clinical holds, labelling changes, and regulatory guidelines across †80+ jurisdictions (^[6] clarivate.com). Regulatory Intelligence supports strategy by alerting users to evolving rules (pharmacopoeia, device approvals, safety directives) and by providing lead-lag analyses of multi-national filings. Clarivate reports the content spans the full range from New Drug/Certificate filings to adverse event reporting laws (including devices and in vitro diagnostics). The recent AI **Regulatory Assistant** feature (Aug 2025) further empowers regulatory teams by enabling natural-language Q&A against this dataset (^[12] clarivate.com) (^[15] clarivate.com).
- Cortellis CMC Intelligence.** Details manufacturing and formulation data for small-molecule drugs. This module, formerly known as Thomson Reuters CMC, provides granular chemistry, manufacturing and control (CMC) information on filings in 130+ countries (^[40] clarivate.com). It simplifies regulatory preparing by giving chemists and regulatory experts a searchable database of global DMFs/ASMFs, manufacturing sources, and formulation attributes.
- Cortellis Generics & Product Intelligence (Newport).** Focused on the generics/pharmaceutical-supply sector, this tool was launched in 2020 to replace Clarivate's earlier "Newport" platform (^[35] ir.clarivate.com). It consolidates generics market performance (sales, consumption), active ingredient (API) supplier data, and patent litigation (e.g. USPTO Paragraph IV challenges) into a single application (^[35] ir.clarivate.com) (^[33] ir.clarivate.com). This allows generics manufacturers and API producers to identify market opportunities and manage supply chain risks. For instance, Cortellis Generics collates over 1.2 million patents and millions of sales records to help users defend market share and target new products (^[35] ir.clarivate.com) (^[7] clarivate.com).
- Cortellis Deals Intelligence.** A commercialization-focused module that provides term books and preclinical/clinical deal data for licensing, joint ventures and M&A. It aggregates transaction details (financials, deal structure) from public filings and Clarivate's Dealogic sources. This helps business development teams benchmark partnership terms and valuation.
- Cortellis Drug Discovery Intelligence (Integrity & Predictive).** Spanning target discovery to preclinical, this encompasses the **Integrity** database and related tools, capturing chemistry and pharmacology knowledge. Integrity contains ~540,000+ bioactive compounds and 2.4 million pharmacological studies with associated targets (^[8] clarivate.com). It is used to validate targets, understand mechanism-of-action, and anticipate toxicity. In 2019 Clarivate also added AI-driven predictive tools within Cortellis (e.g. the "Drug Timeline and Success Rates" model) to forecast pipeline outcomes (^[41] ir.clarivate.com). Additionally, Cortellis works with Quantitative Systems Biology (e.g. **MetaCore**) to connect 'omics data: MetaCore provides 1.7 million+ molecular interactions and pathway networks for systems-level analysis (^[9] clarivate.com). A Qiagen partnership now links Cortellis content (pathways, targets) with QIAGEN's Ingenuity Pathway Analysis to help interpret experimental data.
- Cortellis Digital Health Intelligence.** A niche module (released 2019) covering digital therapeutics and health tech. It mines the ecosystem of wearable devices, mobile health apps, telemedicine platforms and related partnerships. It includes curated data such as ~6,000 press releases about digital-health products, 4,000+ independent app reviews, and 3,000+ digital health deals (^[4] ir.clarivate.com). By integrating this with Cortellis pipeline/trials data, users can analyze, for example, how new diabetes apps may affect a drug's market. Digital Health Intelligence aims to fill gaps left by traditional pharma databases, reflecting the trend that 64% of patients and 62% of hospitals now use digital health tools (^[42] ir.clarivate.com).
- Cortellis Safety & Epidemiology (Off-X).** Cortellis also incorporates Clarivate's **Off-X** safety database (post-market surveillance) and epidemiology data to support pharmacovigilance and outcomes research. While not detailed here, Off-X includes real-world safety profiles and reported adverse events. In combination with Cortellis's preclinical data, this gives users a 360° view of a drug's benefit-risk profile.

Key Data Coverage: The table below highlights some key data statistics across Cortellis modules:

Cortellis Module	Coverage / Data Points
Competitive & BD Intelligence (Pipeline, Deals, Trials)	>70,000 pipeline targets; >90,000 licensing/M&A deals; >325,000 registered clinical trials ^[5] clarivate.com).
Regulatory Intelligence	Global drug/biologics/device regulatory information across 80+ countries ^[6] clarivate.com).
CMC Intelligence	Granular small-molecule CMC (chemistry/manufacturing) data for approvals/filings in 130+ countries ^[40] clarivate.com).
Generics Intelligence (Newport)	1.2M+ patents covering 66,000+ companies in 77 countries ^[7] clarivate.com); includes API manufacturer and litigation data ^[35] ir.clarivate.com).
Drug Discovery Intelligence (Integrity/Pathways)	540,000+ bioactive compounds; 2.4M+ pharmacology studies; 5,700+ drug targets ^[8] clarivate.com). (MetaCore): 1.7M+ molecular interactions; 1,600+ pathway maps; 230k+ gene-disease links ^[9] clarivate.com).
Digital Health Intelligence	~6,000 press releases on health-tech; 4,000+ digital health app reviews; 3,000+ digital health and virtual care deals ^[4] ir.clarivate.com).

Table: Selected Cortellis modules with example data coverage (2019–2020 figures, as reported by Clarivate).

Data Quality and Curation

A distinguishing feature of Cortellis is its emphasis on **curated, high-quality data**. Clarivate employs expert analysts to review and integrate information from peer-reviewed publications, regulatory filings, patents, company reports and news. This human curation reduces noise and ensures consistency across sources. For instance, Cortellis’s clinical trial database is not just a mirror of [ClinicalTrials.gov](https://clinicaltrials.gov); it is enriched with history-tracking, investigator details and combined global registry feeds. Likewise, regulatory approvals are abstracted from official agencies worldwide rather than relying on secondary summaries. Clarivate’s longevity (35+ years in life science data) means Cortellis includes legacy content far beyond competitors’ archives ^[18] intuitionlabs.ai).

However, this depth means the system can be complex. Users have remarked that overlapping information among Clarivate’s own products (e.g. Cortellis vs. Derwent Intelligences) can be confusing, and the learning curve is steep ^[18] intuitionlabs.ai). Moreover, licensing Cortellis can be expensive, potentially limiting access for smaller firms. Nonetheless, major pharmaceutical companies, CROs and research institutions worldwide rely on Cortellis in everyday work. Clarivate itself notes over *3,000 life sciences clients* (including all “top 30” pharma companies globally) use its healthcare analytics ^[43] clarivate.com).

Technological Innovations (AI and Analytics)

Recent years have seen Clarivate integrating advanced technologies into Cortellis. Two notable developments are its generative AI search and conversational assistants.

In August 2023, Clarivate unveiled a **GenAI-powered search platform** for life sciences ^[10] clarivate.com). This patent-pending system indexes billions of proprietary data points from across Cortellis (and related products like Disease Landscape & Forecast) and layers on natural language processing. Researchers can ask complex questions (e.g. “Which biotech is advancing PD-1 inhibitors in China?”) and receive immediate synthesized answers with cited evidence ^[10] clarivate.com) ^[11] clarivate.com). Features include an internal knowledge graph, contextual summarization, and clear result segmentation to minimize AI hallucinations ^[44] clarivate.com). Initially launched in beta, this platform promises to “transform the paradigm of disparate, siloed data sources” by allowing intuitive, cross-domain data exploration ^[10] clarivate.com) ^[44] clarivate.com). Clarivate plans to continually add more Cortellis modules and data feeds to the system ^[45] clarivate.com).

The **AI-powered Regulatory Assistant** — launched in beta in August 2025 and made generally available to all Cortellis Regulatory Intelligence customers in December 2025 — is a live example of applied AI in Cortellis ^[13] clarivate.com).

Integrated into the RegInt module, it allows regulatory staff to pose questions in natural English (or other languages) about submission requirements or guidelines and get instant, referenced answers (^[12] clarivate.com). Clarivate emphasizes that this assistant was developed with customer input to “meet the real-world needs” of regulatory professionals (^[46] clarivate.com). In its beta tests, Moderna highlighted that the AI assistant “will save significant time and resources” for internal regulatory queries, dramatically reducing the manual effort of reading voluminous regulation documents (^[15] clarivate.com). Key capabilities include quick document summarization, side-by-side comparison of draft and final guidance, conversational chat history for continuity, and multilingual support. In March 2026, Clarivate extended the assistant’s reach by announcing integration of Cortellis Regulatory Intelligence with Anthropic’s Claude AI via the open Model Context Protocol (MCP), making authoritative regulatory data available directly within Claude workflows (^[39] stocktitan.net). Together, these AI advances make Cortellis not just a static repository, but a dynamic, AI-native decision-support toolkit.

Beyond AI, Cortellis leverages big data architecture. Its cloud infrastructure (built on AWS) enables scalable on-demand analytics and updates. As Clarivate reports, new data assets and analytics can be «rapidly deployed» to all customers (^[2] clarivate.com). This means, for example, that when a new regulatory policy is published or a major trial result appears, it is quickly ingested and made searchable. Continuous integration of data from partner APIs or Clarivate’s own acquisitions (e.g. health systems data from recently acquired companies) further enriches Cortellis’s offerings.

Case Studies and Real-World Applications

Biotech R&D Integration: In its earliest days, Cortellis’s API-led approach drew high praise. Dr. William Hayes of Biogen Idec noted in 2012 that Cortellis “exceed [ed] my expectations” by allowing Thomson Reuters content to flow directly into the company’s internal systems (^[14] www.fiercebiotech.com). This ability to integrate Cortellis data (drug pipelines, targets, patents) into bespoke dashboards and analytics was seen as a breakthrough for research collaboration. Modern Cortellis continues such integration: for instance, Clarivate’s Science Group partners with companies like QIAGEN to merge Cortellis target/pathway data with genomic analysis tools (e.g. Ingenuity Pathway Analysis), enabling researchers to correlate high-throughput ‘omics data with curated drug knowledge.

Regulatory Efficiency at Moderna: In a recent pilot, Moderna’s regulatory intelligence team used Cortellis’s new AI assistant. Regulatory Director Janeen Skutnik-Wilkinson reported that the tool “will save us significant time and resources compared to searching manually” (^[15] clarivate.com). Tracking global regulatory requirements is a daunting task; Cortellis’s AI assistant streamlines it by answering questions like “Does China require a paediatric study for new vaccines?” with immediate, cited guidance. This augments Moderna’s capacity to respond quickly to changing rules in multiple markets.

Generics and Supply Chain: Generic drug makers face intense margin pressure and supply disruptions. Cortellis Generics Intelligence helps such firms identify opportunities and risks. For example, a generic manufacturer planning a new version of an antidepressant could use the platform to see the patent expiry dates, track ongoing Paragraph IV challenges, find reliable API suppliers, and model market demand – all within one interface. While no public case study names a client, Clarivate’s news release highlights how this single-application approach can help “sourcing, business development, and portfolio teams” work together to launch generics by understanding markets, patents, and competition (^[35] ir.clarivate.com).

Portfolio Strategy: In many pharma companies, Cortellis Competitive Intelligence dashboards are standard. Portfolio managers use Cortellis to score assets by risk–reward or to benchmark competitors. For instance, companies filing New Drug Applications (NDAs) often analyze Cortellis’ historical success-rate data (Drug Timeline and Success Rates model (^[41] ir.clarivate.com)) to set realistic timelines. With 80% of first-in-class and 91% of breakthrough-designated drugs (2017 data) having been tracked in Cortellis, executives trust it as a predictive tool (^[27] clarivate.com).

Academic and Government Use: Some national bodies also leverage Cortellis. The blog analysis by Stephen Williams notes Norway’s DIKU selected Web of Science and Clarivate tools for research assessment; Cortellis, while industry-focused, could similarly inform government R&D planning by revealing trends in domestic and global pipelines (^[47]

pharmaceuticalintelligence.com). Clarivate also runs educational programs, and universities with strong pharma partnerships (e.g. biotech institutes) subscribe to Cortellis as part of training future scientists in data-driven R&D.

Comparative Perspective and Competitors

Cortellis operates in a competitive market of life-science intelligence vendors. Its main alternatives include **Evaluate (Norstella)**, **IQVIA**, and **Citeline (Norstella, formerly Informa Pharma Intelligence)**. Evaluate is renowned for consensus sales forecasts and pharmaceutical portfolio analytics, particularly its “Evaluate Pharma” and Omnium forecasting platform ⁽¹⁶⁾ intuitionlabs.ai). IQVIA (the IMS Health/Quintiles giant) dominates commercial data (prescriptions, insurance claims, real-world evidence) ⁽⁴⁸⁾ intuitionlabs.ai). Citeline (now part of Norstella alongside Evaluate) offers PharmaProjects and TrialTrove for pipeline/trial tracking and the Pink Sheet for regulatory news.

Compared to these, Clarivate’s Cortellis emphasizes **curated R&D intelligence across the entire lifecycle** ⁽²⁸⁾ intuitionlabs.ai). Unlike Evaluate (which focuses on sales and consensus forecasts) or IQVIA (which focuses on prescribing and claims data), Cortellis’s strength is *depth of scientific detail* – patents, assay data, regulatory filings – built up over decades ⁽¹⁸⁾ intuitionlabs.ai). Clarivate highlights that “billions of data points” and 30+ years of legacy data underpin Cortellis ⁽¹⁰⁾ clarivate.com) ⁽¹⁸⁾ intuitionlabs.ai). This makes Cortellis very powerful for R&D strategy and due diligence. However, some analysts note that its coverage overlaps with Clarivate’s own Decision Resources and other Clarivate assets, potentially confusing users ⁽¹⁸⁾ intuitionlabs.ai). Additionally, because Cortellis is subscription-based and highly detailed, it may be less suitable for purely commercial functions than IQVIA or Evaluate’s products.

In practice, many sophisticated organizations use multiple sources in tandem. For example, a global pharma company might rely on IQVIA for sales forecasting, Evaluate for high-level analytics, and Cortellis for the scientific pipeline perspective ⁽⁴⁹⁾ intuitionlabs.ai). Clarivate positions Cortellis as complementary – “an end-to-end, industry-leading data and analytics provider” ⁽⁵⁰⁾ clarivate.com) – rather than requiring Cortellis alone to do everything. Clients often cite Clarivate’s unique combination of content curation and expert analyst support (e.g. Pink Sheet commentary) as distinguishing factors.

Data Evidence and Analysis

Market Size & Growth: The market for life sciences analytics is significant and growing. Clarivate’s own research pegged the global life sciences analytics market at roughly \$19–25 billion (USD), with double-digit growth rates ⁽⁵¹⁾ clarivate.com) ⁽⁵²⁾ ir.clarivate.com). Much of this investment is driven by demand for competitive and clinical intelligence in a crowded R&D landscape. Cortellis’s high penetration (e.g. used in 80–91% of groundbreaking filings) suggests it plays a major role in that market ⁽²⁷⁾ clarivate.com).

Cortellis Content Volume: Quantitative data illustrate Cortellis’s scope. The **Competitive/Trials domain** alone covers over 70k pipeline entries, 90k deals, and 325k trials ⁽⁵⁾ clarivate.com). In **Regulatory**, Cortellis tracks filings in 80 countries ⁽⁶⁾ clarivate.com). The **CMC** module spans data in 130+ countries ⁽⁴⁰⁾ clarivate.com). The **Generics** database holds 1.2 million patents and company info ⁽⁷⁾ clarivate.com). The **Discovery** resources cover half a million compounds and 5,700+ targets ⁽⁸⁾ clarivate.com). The **Digital Health** module contains thousands of records (as noted above) ⁽⁴⁾ ir.clarivate.com). Such scale – billions of entries total – is confirmed by Clarivate’s statements that Cortellis includes “billions of best-in-class data assets” ⁽⁵³⁾ clarivate.com).

Data Freshness: Clarivate emphasizes real-time updating. Cortellis pulls from live feeds (e.g. regulatory bulletins, corporate press releases) so that new approvals or trial starts appear almost immediately. Clarivate’s marketing reports claim that Cortellis Cloud allows “immediate adoption of the latest content and product enhancements” as they become available ⁽²⁾ clarivate.com). For full-year 2025, Clarivate reported total company revenues of \$2.46 billion, with the Life Sciences & Healthcare segment contributing \$389.8 million (down 6.9% year-over-year) ⁽¹⁹⁾ clarivate.com).

Industry Impact Metrics: Some metrics reflect Cortellis's impact on outcomes. Clarivate cites independent data showing that in 2017 "80% of U.S. companies filing NMEs" and 91% of companies with breakthrough therapies were informed by Cortellis intelligence (^[27] clarivate.com). In pharmaceutical business review analyses, Cortellis is credited with helping companies identify strong targets and avoid failures. (For instance, the predictive Success Rates model in Cortellis boasts ~4× better accuracy in forecasting Phase I success than traditional methods (^[16] intuitionlabs.ai).) While proprietary, this kind of performance claim underscores Cortellis's reputation for enhancing R&D productivity.

Implications and Future Directions

Cortellis's continued evolution has broad implications for the life sciences industry. By centralizing intelligence, it enables faster, cross-functional decision-making: R&D teams can collaborate more closely with portfolio strategy, regulatory affairs, and commercial groups when all share a common data platform. For example, pipeline data in Cortellis helps marketing and health economics teams plan market entry far in advance, anticipating where regulatory hurdles or competitor breakthroughs might arise.

The integration of AI and cloud capabilities suggests a future of even greater automation. Clarivate's GenAI search and conversational tools reduce the labor of information gathering. As these mature, we may see Cortellis not just as a database but as an AI assistant in drug development workflows. For instance, an investigator could ask Cortellis for "the likelihood of FDA approval for a CNS drug with this biomarker in Phase II" and receive a data-driven answer. However, such use raises concerns about AI reliability and data privacy; Clarivate will need to ensure transparent "explainable AI" and maintain data security as it expands these features.

Another important trend is the increasing convergence of real-world evidence (RWE) with Cortellis. Currently, Cortellis focuses on trial and regulatory data over claims and patient records (the latter being IQVIA's domain). But as RWE gains regulatory acceptance, Clarivate has opportunities to augment Cortellis with selected real-world datasets (e.g. epidemiology bases, payer data). In fact, Clarivate has already been acquiring real-world data assets (e.g. Patient Connect) (^[54] ir.clarivate.com). Embedding RWE into workflows like site feasibility and market analysis could make Cortellis an even more comprehensive tool.

The launch of modules like Digital Health Intelligence and Generics Intelligence shows Clarivate adapting Cortellis to evolving markets (mobile health, biosimilars). The 2024 acquisition of MotionHall, a Silicon Valley AI start-up, further signals Clarivate's commitment to AI-driven intelligence: MotionHall's IP is being used to enhance Cortellis search, improve data quality and coverage, and power a new Business Development & Licensing Enterprise Workbench (^[26] clarivate.com). Similarly, the March 2026 integration of Cortellis Regulatory Intelligence with Anthropic's Claude AI via MCP points toward a future where Cortellis data flows seamlessly into customers' existing AI-assisted workflows, rather than requiring users to work within a single proprietary interface.

However, the most significant development for Cortellis's future is Clarivate's February 2026 announcement that it is exploring a sale of its entire Life Sciences & Healthcare segment (^[19] clarivate.com). This strategic move — driven by Clarivate's desire to focus on its Academia & Government and Intellectual Property segments and reduce its \$4.5 billion debt load — introduces uncertainty about Cortellis's ownership and direction. Potential acquirers could include private equity firms, strategic buyers like IQVIA or Norstella, or technology companies seeking to enter the life sciences data market. While there can be no assurance a transaction will be completed, a change of ownership could reshape Cortellis's product roadmap, pricing, and integration strategy. For existing customers, the key question is whether a new owner would continue the platform's trajectory of innovation or prioritize cost-cutting.

Despite this uncertainty, pharma companies remain deeply reliant on the Cortellis ecosystem. This dependency raises broader industry questions about data portability and interoperability standards, ensuring that Cortellis data can be integrated with other tools and models regardless of ownership changes.

- [12] <https://clarivate.com/news/clarivate-launches-ai-powered-regulatory-assistant/#:~:for%...>
- [13] <https://clarivate.com/news/clarivate-presents-cortellis-regulatory-ai-assistant/>
- [14] <https://www.fiercebitech.com/biotech/thomson-reuters-cortellis-drives-drug-discovery-and-development-powerful-new-web-services#:~:Deci...>
- [15] <https://clarivate.com/news/clarivate-launches-ai-powered-regulatory-assistant/#:~:Janee...>
- [16] <https://intuitionlabs.ai/articles/pharmaceutical-market-intelligence-providers#:~:4...>
- [17] <https://intuitionlabs.ai/articles/pharmaceutical-market-intelligence-providers#:~:2...>
- [18] <https://intuitionlabs.ai/articles/pharmaceutical-market-intelligence-providers#:~:reso...>
- [19] <https://clarivate.com/news/clarivate-reports-fourth-quarter-and-full-year-2025-results/>
- [20] <https://pharmaceuticalintelligence.com/2024/04/16/the-health-care-dossier-on-clarivate-plc-how-cortellis-is-changing-the-life-sciences-industry/#:~:Clari...>
- [21] <https://www.fiercebitech.com/biotech/thomson-reuters-cortellis-drives-drug-discovery-and-development-powerful-new-web-services#:~:PHILA...>
- [22] <https://www.fiercebitech.com/biotech/thomson-reuters-cortellis-drives-drug-discovery-and-development-powerful-new-web-services#:~:Each%...>
- [23] <https://www.fiercebitech.com/biotech/thomson-reuters-cortellis-drives-drug-discovery-and-development-powerful-new-web-services#:~:;inte...>
- [24] <https://clarivate.com/news/clarivate-analytics-to-acquire-decision-resources-group-creating-a-leading-global-provider-of-data-driven-solutions-to-the-life-sciences-industry/#:~:Jerre...>
- [25] <https://clarivate.com/news/clarivate-analytics-to-acquire-decision-resources-group-creating-a-leading-global-provider-of-data-driven-solutions-to-the-life-sciences-industry/#:~:;in%2...>
- [26] <https://clarivate.com/news/clarivate-acquires-ai-start-up-to-accelerate-strategy-and-business-development-success-for-life-sciences-healthcare-clients/>
- [27] <https://clarivate.com/news/clarivate-analytics-launches-cortellis-cloud-to-accelerate-rd-innovation/#:~:accel...>
- [28] <https://intuitionlabs.ai/articles/pharmaceutical-market-intelligence-providers#:~:Clari...>
- [29] <https://clarivate.com/news/clarivate-analytics-launches-cortellis-cloud-to-accelerate-rd-innovation/#:~:Phila...>
- [30] <https://clarivate.com/news/clarivate-analytics-launches-cortellis-cloud-to-accelerate-rd-innovation/#:~:provi...>
- [31] <https://ir.clarivate.com/news-events/press-releases/news-details/2020/Clarivate-Introduces-Next-Generation-Insights-Platform-with-Cortellis-Generics-Intelligence/default.aspx/1000/#:~:LONDO...>
- [32] <https://ir.clarivate.com/news-events/press-releases/news-details/2020/Clarivate-Introduces-Next-Generation-Insights-Platform-with-Cortellis-Generics-Intelligence/default.aspx/1000/#:~:appli...>
- [33] <https://ir.clarivate.com/news-events/press-releases/news-details/2020/Clarivate-Introduces-Next-Generation-Insights-Platform-with-Cortellis-Generics-Intelligence/default.aspx/1000/#:~:This%...>
- [34] <https://ir.clarivate.com/news-events/press-releases/news-details/2019/Clarivate-Analytics-launches-Cortellis-Digital-Health-Intelligence-a-first-of-its-kind-solution-covering-the-global-digital-health-ecosystem/default.aspx#:~:LONDO...>
- [35] <https://ir.clarivate.com/news-events/press-releases/news-details/2020/Clarivate-Introduces-Next-Generation-Insights-Platform-with-Cortellis-Generics-Intelligence/default.aspx/1000/#:~:Corte...>
- [36] <https://ir.clarivate.com/news-events/press-releases/news-details/2019/Clarivate-Analytics-launches-Cortellis-Digital-Health-Intelligence-a-first-of-its-kind-solution-covering-the-global-digital-health-ecosystem/default.aspx#:~:Corte...>

- [37] <https://clarivate.com/news/clarivate-analytics-to-acquire-decision-resources-group-creating-a-leading-global-provider-of-data-driven-solutions-to-the-life-sciences-industry/#:~:data%...>
 - [38] <https://clarivate.com/news/clarivate-launches-enhanced-search-powered-by-generative-artificial-intelligence/#:~:effic...>
 - [39] <https://www.stocktitan.net/news/CLVT/clarivate-expands-access-to-trusted-regulatory-intelligence-within-41340dfxd5en.html>
 - [40] <https://clarivate.com/news/clarivate-analytics-launches-cortellis-cloud-to-accelerate-rd-innovation/#:~:cont...>
 - [41] <https://ir.clarivate.com/news-events/press-releases/news-details/2019/Clarivate-Analytics-Reports-First-Quarter-2019-Results/default.aspx#:~:Scien...>
 - [42] <https://ir.clarivate.com/news-events/press-releases/news-details/2019/Clarivate-Analytics-launches-Cortellis-Digital-Health-Intelligence-a-first-of-its-kind-solution-covering-the-global-digital-health-ecosystem/default.aspx#:~:The%C...>
 - [43] <https://clarivate.com/cortellis/solutions/competitive-intelligence-and-analytics/#:~:...>
 - [44] <https://clarivate.com/news/clarivate-launches-enhanced-search-powered-by-generative-artificial-intelligence/#:~:funct...>
 - [45] <https://clarivate.com/news/clarivate-launches-enhanced-search-powered-by-generative-artificial-intelligence/#:~:integ...>
 - [46] <https://clarivate.com/news/clarivate-launches-ai-powered-regulatory-assistant/#:~:Londo...>
 - [47] <https://pharmaceuticalintelligence.com/2024/04/16/the-health-care-dossier-on-clarivate-plc-how-cortellis-is-changing-the-life-sciences-industry/#:~:6,saf...>
 - [48] <https://intuitionlabs.ai/articles/pharmaceutical-market-intelligence-providers#:~:IQVIA...>
 - [49] <https://intuitionlabs.ai/articles/pharmaceutical-market-intelligence-providers#:~:Clari...>
 - [50] <https://clarivate.com/news/clarivate-analytics-to-acquire-decision-resources-group-creating-a-leading-global-provider-of-data-driven-solutions-to-the-life-sciences-industry/#:~:data%...>
 - [51] <https://clarivate.com/news/clarivate-analytics-to-acquire-decision-resources-group-creating-a-leading-global-provider-of-data-driven-solutions-to-the-life-sciences-industry/#:~:DRG%2...>
 - [52] <https://ir.clarivate.com/news-events/press-releases/news-details/2023/Clarivate-Reports-Fourth-Quarter-and-Full-Year-2022-Results/default.aspx/1000#:~:New%...>
 - [53] <https://clarivate.com/news/clarivate-launches-enhanced-search-powered-by-generative-artificial-intelligence/#:~:Henry...>
 - [54] <https://ir.clarivate.com/news-events/press-releases/news-details/2023/Clarivate-Reports-Fourth-Quarter-and-Full-Year-2022-Results/default.aspx/1000#:~:Selec...>
 - [55] <https://clarivate.com/news/clarivate-analytics-launches-cortellis-cloud-to-accelerate-rd-innovation/#:~:insig...>
 - [56] <https://ir.clarivate.com/news-events/press-releases/news-details/2019/Clarivate-Analytics-Reports-First-Quarter-2019-Results/default.aspx#:~:First...>
-

IntuitionLabs - Industry Leadership & Services

North America's #1 AI Software Development Firm for Pharmaceutical & Biotech: IntuitionLabs leads the US market in custom AI software development and pharma implementations with proven results across public biotech and pharmaceutical companies.

Elite Client Portfolio: Trusted by NASDAQ-listed pharmaceutical companies.

Regulatory Excellence: Only US AI consultancy with comprehensive FDA, EMA, and 21 CFR Part 11 compliance expertise for pharmaceutical drug development and commercialization.

Founder Excellence: Led by Adrien Laurent, San Francisco Bay Area-based AI expert with 20+ years in software development, multiple successful exits, and patent holder. Recognized as one of the top AI experts in the USA.

Custom AI Software Development: Build tailored pharmaceutical AI applications, custom CRMs, chatbots, and ERP systems with advanced analytics and regulatory compliance capabilities.

Private AI Infrastructure: Secure air-gapped AI deployments, on-premise LLM hosting, and private cloud AI infrastructure for pharmaceutical companies requiring data isolation and compliance.

Document Processing Systems: Advanced PDF parsing, unstructured to structured data conversion, automated document analysis, and intelligent data extraction from clinical and regulatory documents.

Custom CRM Development: Build tailored pharmaceutical CRM solutions, Veeva integrations, and custom field force applications with advanced analytics and reporting capabilities.

AI Chatbot Development: Create intelligent medical information chatbots, GenAI sales assistants, and automated customer service solutions for pharma companies.

Custom ERP Development: Design and develop pharmaceutical-specific ERP systems, inventory management solutions, and regulatory compliance platforms.

Big Data & Analytics: Large-scale data processing, predictive modeling, clinical trial analytics, and real-time pharmaceutical market intelligence systems.

Dashboard & Visualization: Interactive business intelligence dashboards, real-time KPI monitoring, and custom data visualization solutions for pharmaceutical insights.

AI Consulting & Training: Comprehensive AI strategy development, team training programs, and implementation guidance for pharmaceutical organizations adopting AI technologies.

Contact founder Adrien Laurent and team at <https://intuitionlabs.ai/contact> for a consultation.

DISCLAIMER

The information contained in this document is provided for educational and informational purposes only. We make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability, or availability of the information contained herein.

Any reliance you place on such information is strictly at your own risk. In no event will IntuitionLabs.ai or its representatives be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from the use of information presented in this document.

This document may contain content generated with the assistance of artificial intelligence technologies. AI-generated content may contain errors, omissions, or inaccuracies. Readers are advised to independently verify any critical information before acting upon it.

All product names, logos, brands, trademarks, and registered trademarks mentioned in this document are the property of their respective owners. All company, product, and service names used in this document are for identification purposes only. Use of these names, logos, trademarks, and brands does not imply endorsement by the respective trademark holders.

IntuitionLabs.ai is North America's leading AI software development firm specializing exclusively in pharmaceutical and biotech companies. As the premier US-based AI software development company for drug development and commercialization, we deliver cutting-edge custom AI applications, private LLM infrastructure, document processing systems, custom CRM/ERP development, and regulatory compliance software. Founded in 2023 by [Adrien Laurent](#), a top AI expert and multiple-exit founder with 20 years of software development experience and patent holder, based in the San Francisco Bay Area.

This document does not constitute professional or legal advice. For specific guidance related to your business needs, please consult with appropriate qualified professionals.

© 2025 IntuitionLabs.ai. All rights reserved.